ArticleCell reports. Medicine2022
SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer.
Open access · goldAbstract read
In one paragraph
Article in Cell reports. Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 34 citations in OpenAlex.
- Article
- Targeting prostate adenocarcinoma tumor microenvironment via cancer nanotheranostics: a comprehensive update on improved roadmap for disease diagnosis, therapy and management.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- HSP27 functional switch drives castration-resistant prostate cancer via mTOR pathway activation, highlighting promising combination therapies.Journal of experimental & clinical cancer research : CR · 2026Article
- Identification of glycolysis -correlative features for predicting prognosis and investigating immune landscape in prostate cancer.BMC cancer · 2026Article
- Diversity of Gut Microbiota and Metabolites in Benign Prostatic Hyperplasia with Different Prostate Volumes.European urology open science · 2026Article
- Identification of a Novel Trifluoromethyl-Bearing Flavonoid as a Promising Androgen Receptor Antagonist: Structure-Based Virtual Screening and In Vitro Study.Computational and structural biotechnology journal · 2026Article
- Extracellular Domain Shedding of TROP2 Activates EGFR Signaling to Drive Prostate Cancer Metastasis.Cancer research · 2025Article
- HSP90 co-regulates the formation and nuclear distribution of the glycolytic output complex to promote resistance and poor prognosis in gastric cancer patients.Journal of translational medicine · 2025Article
- Bibliometric analysis of glycolysis and prostate cancer research from 2004 to 2024.Discover oncology · 2025Article
- Identification of a New Pentafluorosulfanyl-Substituted Chalcone with Activity Against Hepatoma and Human Parasites.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Androgen-targeted hsa_circ_0085121 encodes a novel protein and improves the development of prostate cancer through facilitating the activity of PI3K/Akt/mTOR pathway and enhancing AR-V7 alternative splicing.Cell death & disease · 2024Article
- Hsp90 Promotes Gastric Cancer Cell Metastasis and Stemness by Regulating the Regional Distribution of Glycolysis-Related Metabolic Enzymes in the Cytoplasm.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Activity-based protein profiling and global proteome analysis reveal MASTL as a potential therapeutic target in gastric cancer.Cell communication and signaling : CCS · 2024Article
- Mortalin promotes the evolution of androgen-independent prostate cancer through Wnt/β-catenin signaling pathway.Cancer cell international · 2024Article
- Computational Modeling to Identify Drugs Targeting Metastatic Castration-Resistant Prostate Cancer Characterized by Heightened Glycolysis.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity.Cancer research · 2024Article
- HSP90 inhibition suppresses tumor glycolytic flux to potentiate the therapeutic efficacy of radiotherapy for head and neck cancer.Science advances · 2024Article
- Design and Characterization of a Novel eEF2K Degrader with Potent Therapeutic Efficacy Against Triple-Negative Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Inhibiting anti-angiogenic VEGF165b activates a miR-17-20a-Calcipressin-3 pathway that revascularizes ischemic muscle in peripheral artery disease.Communications medicine · 2024Article
- Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.Molecular cancer · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 2 institutions in 1 country.
Meghan A RiceDepartment of Radiology, Stanford University, Stanford, CA 94305, USA.
Vineet KumarDepartment of Radiation Oncology, Stanford University, Stanford, CA 94305, USA.
Dhanir TailorDepartment of Radiation Oncology, Stanford University, Stanford, CA 94305, USA.
Fernando Jose Garcia-MarquesDepartment of Radiology, Stanford University, Stanford, CA 94305, USA.
En-Chi HsuDepartment of Radiology, Stanford University, Stanford, CA 94305, USA.
Shiqin LiuDepartment of Radiology, Stanford University, Stanford, CA 94305, USA.
Abel BermudezDepartment of Radiology, Stanford University, Stanford, CA 94305, USA.
Vijayalakshmi KanchustambhamDepartment of Chemistry, Stanford University, Stanford, CA 94305, USA.
Vishnu ShankarDepartment of Chemistry, Stanford University, Stanford, CA 94305, USA.
Zintis IndeDepartment of Biology, Stanford University, Stanford, CA 94305, USA.
Busola Ruth AlabiDepartment of Radiology, Stanford University, Stanford, CA 94305, USA.
Arvind MurugananthamDepartment of Radiology, Stanford University, Stanford, CA 94305, USA.
Michelle ShenDepartment of Radiology, Stanford University, Stanford, CA 94305, USA.
Mallesh PandralaDepartment of Radiation Oncology, Stanford University, Stanford, CA 94305, USA.
Rosalie NolleyDepartment of Urology, Stanford University, Stanford, CA 94305, USA.
Merve AslanDepartment of Radiology, Stanford University, Stanford, CA 94305, USA.
Ali GhoochaniDepartment of Radiology, Stanford University, Stanford, CA 94305, USA.
Arushi AgarwalDepartment of Radiology, Stanford University, Stanford, CA 94305, USA.
Mark BuckupDepartment of Radiology, Stanford University, Stanford, CA 94305, USA.
Manoj KumarDepartment of Radiology, Stanford University, Stanford, CA 94305, USA.
Catherine C GoingDepartment of Radiology, Stanford University, Stanford, CA 94305, USA.
Donna M PeehlDepartment of Urology, Stanford University, Stanford, CA 94305, USA.
Scott J DixonDepartment of Biology, Stanford University, Stanford, CA 94305, USA.
Richard N ZareDepartment of Chemistry, Stanford University, Stanford, CA 94305, USA.
James D BrooksCanary Center at Stanford for Cancer Early Detection, Stanford University, Stanford, CA 94305, USA.
Sharon J PitteriDepartment of Radiology, Stanford University, Stanford, CA 94305, USA.
Sanjay V MalhotraDepartment of Radiation Oncology, Stanford University, Stanford, CA 94305, USA.
Tanya StoyanovaDepartment of Radiology, Stanford University, Stanford, CA 94305, USA.
Stanford University · USUniversity of California, San Francisco · US
Funding
Leveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1MStanford Molecular and Cellular Characterization LaboratoryU01CA196387 · NCI · STANFORD UNIVERSITY · PI BROOKS, JAMES D. · 2015 to 2020
$5.2MCharacterizing the Regulation of FerroptosisR01GM122923 · NIGMS · STANFORD UNIVERSITY · PI Scott Dixon · 2017 to 2026
$3.4MElucidating the Role of Trop2 in Prostate CancerR37CA240822 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Tanya I Stoyanova · 2020 to 2026
$2.5MElucidating the Role of UCHL1 in Aggressive Prostate CancerR01CA244281 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI STOYANOVA, TANYA I · 2020 to 2024
$1.8MThe Development of 4-methylumbelliferone Pro-drugs to Prevent Autoimmune DiabetesR01DK114174 · NIDDK · STANFORD UNIVERSITY · PI BOLLYKY, PAUL L · 2018 to 2020
$1.3MDESI-MS detection of positive margins in kidney cancerR21CA229933 · NCI · STANFORD UNIVERSITY · PI BROOKS, JAMES D., ZARE, RICHARD N · 2018 to 2019
$369kNCI NIH HHS R01 CA244281NCI NIH HHS R21 CA229933NCI NIH HHS R37 CA240822NCI NIH HHS T32 CA009302NCI NIH HHS U01 CA196387NIDDK NIH HHS R01 DK114174NIGMS NIH HHS R01 GM122923
Abstract
Among men, prostate cancer is the second leading cause of cancer-associated mortality, with advanced disease remaining a major clinical challenge. We describe a small molecule, SU086, as a therapeutic strategy for advanced prostate cancer. We demonstrate that SU086 inhibits the growth of prostate cancer cells
Indexed as
Prostatic NeoplasmsProteomicsCell ProliferationGlycolysisHSP90 Heat-Shock ProteinsHumansMaleHSP90 Heat-Shock Proteinscombination therapyglycolysisHSP90metabolismprostate cancertherapeuticstherapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.